HRP20140808T1 - Fosfaplatine i njihova uporaba za lijeäśenje raka rezistentnog na cisplantin i karboplatin - Google Patents
Fosfaplatine i njihova uporaba za lijeäśenje raka rezistentnog na cisplantin i karboplatin Download PDFInfo
- Publication number
- HRP20140808T1 HRP20140808T1 HRP20140808AT HRP20140808T HRP20140808T1 HR P20140808 T1 HRP20140808 T1 HR P20140808T1 HR P20140808A T HRP20140808A T HR P20140808AT HR P20140808 T HRP20140808 T HR P20140808T HR P20140808 T1 HRP20140808 T1 HR P20140808T1
- Authority
- HR
- Croatia
- Prior art keywords
- platinum
- trans
- isolated
- preparation
- complex
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title claims 20
- 229960004562 carboplatin Drugs 0.000 title claims 2
- 190000008236 carboplatin Chemical compound 0.000 title 1
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims 58
- 229910052697 platinum Inorganic materials 0.000 claims 29
- XPPKVPWEQAFLFU-UHFFFAOYSA-N diphosphoric acid Chemical compound OP(O)(=O)OP(O)(O)=O XPPKVPWEQAFLFU-UHFFFAOYSA-N 0.000 claims 24
- 238000000034 method Methods 0.000 claims 23
- 201000011510 cancer Diseases 0.000 claims 19
- 238000002360 preparation method Methods 0.000 claims 18
- 239000000178 monomer Substances 0.000 claims 13
- -1 aliphatic amines Chemical class 0.000 claims 11
- HRGDZIGMBDGFTC-UHFFFAOYSA-N platinum(2+) Chemical compound [Pt+2] HRGDZIGMBDGFTC-UHFFFAOYSA-N 0.000 claims 11
- 239000011541 reaction mixture Substances 0.000 claims 11
- SSJXIUAHEKJCMH-PHDIDXHHSA-N (1r,2r)-cyclohexane-1,2-diamine Chemical compound N[C@@H]1CCCC[C@H]1N SSJXIUAHEKJCMH-PHDIDXHHSA-N 0.000 claims 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims 6
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 claims 6
- 229940061720 alpha hydroxy acid Drugs 0.000 claims 5
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 claims 4
- 150000001280 alpha hydroxy acids Chemical class 0.000 claims 4
- 235000011180 diphosphates Nutrition 0.000 claims 4
- 239000007864 aqueous solution Substances 0.000 claims 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims 2
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 claims 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 claims 2
- 239000003153 chemical reaction reagent Substances 0.000 claims 2
- PAFZNILMFXTMIY-UHFFFAOYSA-N cyclohexylamine Chemical compound NC1CCCCC1 PAFZNILMFXTMIY-UHFFFAOYSA-N 0.000 claims 2
- 229910052736 halogen Inorganic materials 0.000 claims 2
- 150000002367 halogens Chemical class 0.000 claims 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 claims 2
- NDBYXKQCPYUOMI-UHFFFAOYSA-N platinum(4+) Chemical compound [Pt+4] NDBYXKQCPYUOMI-UHFFFAOYSA-N 0.000 claims 2
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 claims 2
- 238000001556 precipitation Methods 0.000 claims 2
- 230000000861 pro-apoptotic effect Effects 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 108020004414 DNA Proteins 0.000 claims 1
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 claims 1
- LIWAQLJGPBVORC-UHFFFAOYSA-N N-ethyl-N-methylamine Natural products CCNC LIWAQLJGPBVORC-UHFFFAOYSA-N 0.000 claims 1
- GVWISOJSERXQBM-UHFFFAOYSA-N N-methyl-N-n-propylamine Natural products CCCNC GVWISOJSERXQBM-UHFFFAOYSA-N 0.000 claims 1
- QCOGKXLOEWLIDC-UHFFFAOYSA-N N-n-butyl-N-methylamine Natural products CCCCNC QCOGKXLOEWLIDC-UHFFFAOYSA-N 0.000 claims 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010041067 Small cell lung cancer Diseases 0.000 claims 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical group [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 claims 1
- 208000024313 Testicular Neoplasms Diseases 0.000 claims 1
- 206010057644 Testis cancer Diseases 0.000 claims 1
- 108091023040 Transcription factor Proteins 0.000 claims 1
- 102000040945 Transcription factor Human genes 0.000 claims 1
- 159000000021 acetate salts Chemical class 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 claims 1
- HQABUPZFAYXKJW-UHFFFAOYSA-N butan-1-amine Chemical compound CCCCN HQABUPZFAYXKJW-UHFFFAOYSA-N 0.000 claims 1
- 150000004648 butanoic acid derivatives Chemical class 0.000 claims 1
- 229960004316 cisplatin Drugs 0.000 claims 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims 1
- 238000001816 cooling Methods 0.000 claims 1
- YMHQVDAATAEZLO-UHFFFAOYSA-N cyclohexane-1,1-diamine Chemical group NC1(N)CCCCC1 YMHQVDAATAEZLO-UHFFFAOYSA-N 0.000 claims 1
- 150000004985 diamines Chemical class 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- XHFGWHUWQXTGAT-UHFFFAOYSA-N dimethylamine hydrochloride Natural products CNC(C)C XHFGWHUWQXTGAT-UHFFFAOYSA-N 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000003916 ethylene diamine group Chemical group 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 229910017604 nitric acid Inorganic materials 0.000 claims 1
- 230000002018 overexpression Effects 0.000 claims 1
- 229960001756 oxaliplatin Drugs 0.000 claims 1
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 claims 1
- 235000011056 potassium acetate Nutrition 0.000 claims 1
- 159000000001 potassium salts Chemical class 0.000 claims 1
- RWMKSKOZLCXHOK-UHFFFAOYSA-M potassium;butanoate Chemical compound [K+].CCCC([O-])=O RWMKSKOZLCXHOK-UHFFFAOYSA-M 0.000 claims 1
- WGYKZJWCGVVSQN-UHFFFAOYSA-N propylamine Chemical compound CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 claims 1
- 230000035484 reaction time Effects 0.000 claims 1
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 1
- 239000001632 sodium acetate Substances 0.000 claims 1
- 235000017281 sodium acetate Nutrition 0.000 claims 1
- MFBOGIVSZKQAPD-UHFFFAOYSA-M sodium butyrate Chemical compound [Na+].CCCC([O-])=O MFBOGIVSZKQAPD-UHFFFAOYSA-M 0.000 claims 1
- 159000000000 sodium salts Chemical class 0.000 claims 1
- 201000003120 testicular cancer Diseases 0.000 claims 1
- 239000003981 vehicle Substances 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
- C07F15/0006—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table compounds of the platinum group
- C07F15/0086—Platinum compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
- A61K31/6615—Compounds having two or more esterified phosphorus acid groups, e.g. inositol triphosphate, phytic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
- A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Inorganic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Claims (25)
1. Pripravak za uporabu u postupku liječenja raka naznačen time da sadrži:
jedan ili više izoliranih monomernih kompleksa platine (II) ili (IV) prema formulama I, II, III i IV:
[image]
[image]
pri čemu svaki R1 i R2 je neovisno odabran od NH3, te supstituiranih ili nesupstituiranih alifatskih amina;
pri čemu svaki R3 je odabran od supstituiranih ili nesupstituiranih alifatskih amina;
pri čemu kada jedan od R1 i R2 je NH3, drugi R1 i R2 nije NH3; te
pri čemu svaki S je neovisno odabran od hidroksida, octene kiseline, maslačne kiseline, te alfa-hidroksi kiselina; ili
izolirana monomerna cis-diamin-trans-dihidrokso(dihidrogen pirofosfato)platina(IV);
ili njihove farmaceutski prihvatljive soli.
2. Pripravak za uporabu u postupku liječenja raka prema zahtjevu 1, naznačen time da su R1 i R2 svaki neovisno odabrani od NH3, metil amina, etil amina, propil amina, izopropil amina, butil amina, te cikloheksan amina.
3. Pripravak za uporabu u postupku liječenja raka prema zahtjevu 1 naznačen time da je R3 odabran od etilendiamina i cikloheksandiamina.
4. Pripravak za uporabu u postupku liječenja raka prema zahtjevu 1, naznačen time da izolirani monomerni kompleks platina je:
1,2-etandiamin(dihidrogen pirofosfato)platina(II), ili
(trans-1,2-cikloheksandiamin)(dihidrogen pirofosfato)platina(II), ili
cis-diamin-trans-dihidrokso(dihidrogen pirofosfato)platina(IV), ili
1,2-etandiamin-trans-dihidrokso(dihidrogen pirofosfato)platina(IV), ili
(trans-1,2-cikloheksandiamin)-trans-dihidrokso(dihidrogen pirofosfato)platina(IV).
5. Pripravak za uporabu u postupku liječenja raka prema zahtjevu 1, naznačen time da izolirani monomerni kompleks platine je (trans-1,2-cikloheksandiamin)(dihidrogen pirofosfato)platina(II).
6. Pripravak za uporabu u postupku liječenja raka prema zahtjevu 1, naznačen time da izolirani monomerni kompleks platine je (trans-1,2-cikloheksandiamin)-trans-dihidrokso(dihidrogen pirofosfato)platina(IV).
7. Pripravak za uporabu u postupku liječenja raka prema zahtjevu 1 naznačen time da sadrži: jedan ili više izoliranih monomernih kompleksa platine koji su odabrani od:
(i) cis-diamin-trans-dihidrokso(dihidrogen pirofosfato)platina(IV);
(ii) 1,2-Etandiamin(dihidrogen pirofosfato)platina (II);
(iii) 1,2-Etandiamin-trans-dihidrokso(dihidrogen pirofosfato)platina(IV);
(iv) (Trans-1 ,2-cikloheksandiamin)(dihidrogen pirofosfato)platina(II);
(v) (Trans-1,2-cikloheksandiamin)-trans-dihidrokso(dihidrogen pirofosfato)platina(IV); i
(vi) njihovih farmaceutski prihvatljivih soli.
8. Pripravak za uporabu u postupku liječenja raka prema zahtjevu 7, naznačen time da je izolirani monomerni kompleks platine stabilan u vodenoj otopini kod pH između oko 6 do oko 8.
9. Pripravak za uporabu u postupku liječenja raka prema zahtjevu 7, naznačen time da izolirani monomerni kompleks platine ne veže DNK.
10. Pripravak za uporabu u postupku liječenja raka prema zahtjevu 7, naznačen time da izolirani monomerni kompleks platina aktivira prekomjernu ekspresiju fas i fas-srodnih transkripcijskih faktora, ili proapoptotičkih gena.
11. Pripravak za uporabu u postupku liječenja raka prema zahtjevu 10, naznačen time da proapoptotički geni su Bak i Bax.
12. Postupak za pripravu izoliranog monomernog kompleksa platina (II) naznačen time da sadrži:
(i) održavanje vodene reakcijske smjese koja sadrži višak pirofosfata i kompleks platine prema formuli V ili VI:
[image]
pri čemu svaki R1 i R2 je neovisno odabran od NH3, te supstituiranih ili nesupstituiranih alifatskih amina,
pri čemu R3 je odabran od supstituiranih ili nesupstituiranih alifatskih amina; te
pri čemu X je neovisno odabran od halogena;
kod temperature od oko 30 do oko 60 stupnjeva Celzija kroz period vremena od oko 12 do oko 18 sati kod pH od oko 7 do oko 9;
(ii) naknadno koncentriranje vodene reakcijske smjese tako da se ne odvija taloženje pirofosfata;
(iii) brzo snižavanje pH reakcijske smjese na pH od manje od 2 dodavanjem kiseline;
pri čemu, izolirani monomerni kompleks platina (II) ima formulu I ili III:
[image]
pri čemu svaki R1 i R2 je neovisno odabran od NH3, te supstituiranih ili nesupstituiranih alifatskih amina;
pri čemu R3 je odabran od supstituiranih ili nesupstituiranih alifatskih diamina; te
pri čemu izolirani monomerni kompleks platine je stabilan u vodenoj otopini kod pH između oko 6 do oko 9.
13. Postupak prema zahtjevu 12, naznačen time da je pripremljeni izolirani monomerni kompleks platine (Trans-1,2-cikloheksandiamin)(dihidrogen pirofosfato)platina(II).
14. Postupak za pripravu izoliranog monomernog kompleksa platina (IV) naznačen time da sadrži:
(i) održavanje vodene reakcijske smjese koja sadrži višak pirofosfata i kompleks platine prema formuli V ili VI:
[image]
pri čemu svaki je R1 i R2 neovisno odabran od NH3, te supstituiranih ili nesupstituiranih alifatskih amina,
pri čemu R3 je odabran od supstituiranih ili nesupstituiranih alifatskih amina, te
pri čemu X je neovisno odabran od halogena;
kod temperature od oko 30 do oko 60 stupnjeva Celzija kroz period vremena od oko 12 do oko 18 sati uz pH od oko 7 do oko 9;
(ii) dodavanje u reakcijsku smjesu vodikovog peroksida, te proizvoljno reagensa odabranog iz skupine koja sadrži soli acetata, soli butirata, te soli alfa-hidroksi kiselina, i njihove kombinacije;
(iii) naknadno koncentriranje vodene reakcijske smjese tako da se ne odvija taloženje pirofosfata;
(iv) brzo snižavanje pH reakcijske smjese na pH od manje od 2 dodavanjem dušične kiseline;
pri čemu izolirani monomerni kompleks platina (IV) ima formulu II ili IV:
[image]
pri čemu svaki R1 i R2 je neovisno odabran od NH3, te supstituiranih ili nesupstituiranih alifatskih amina;
pri čemu R3 je odabran od supstituiranih ili nesupstituiranih alifatskih amina;
pri čemu je svaki S neovisno odabran od hidroksida, octene kiseline, maslačne kiseline, te alfa-hidroksi kiselina; i
pri čemu je izolirani monomerni kompleks platine stabilan u vodenoj otopini kod pH između oko 6 do oko 9.
15. Postupak prema zahtjevu 12 ili zahtjevu 14, naznačen time da je temperatura 40 stupnjeva Celzija i vrijeme reakcije je 15 sati, a pH je između 7 i 8.
16. Postupak prema zahtjevu 12 ili zahtjevu 14, naznačen time da dodatno nakon koncentriranja reakcijske smjese, ili nakon snižavanja pH reakcijske smjese sadrži hlađenje reakcijske smjese do temperature od između 5 stupnjeva Celzija i temperature okoline.
17. Postupak prema zahtjevu 14, naznačen time da je proizvoljni reagens koji se dodaje zajedno s vodikovim peroksidom prije koncentriranja reakcijske smjese odabran od natrijevog acetata, natrijevog butirata, i natrijevih soli alfa-hidroksi kiselina, ili od kalijevog acetata, kalijevog butirata, i kalijevih soli alfa-hidroksi kiselina.
18. Postupak prema zahtjevu 14, naznačen time da je vodikov peroksid u početnoj koncentraciji od 30% vol/vol.
19. Postupak prema zahtjevu 14, naznačen time da je pripremljeni izolirani monomerni kompleks platine:
cis-diamin-trans-dihidrokso(dihidrogen pirofosfato)platina(IV), ili
1,2-Etandiamin-trans-dihidrokso(dihidrogen pirofosfato)platina(IV), ili
Trans-1,2-cikloheksandiamin)-trans-dihidrokso(dihidrogen pirofosfato)platina(IV).
20. Pripravak koji sadrži terapeutski učinkovitu količinu barem jednog izoliranog monomernog kompleksa platine odabranog od diamin(dihidrogen pirofosfato)platina(II) i kompleksa prema zahtjevu 1 i barem jednog farmaceutski prihvatljivog nosača, sredstva za razrjeđivanje, adjuvanta, ili vehikula, naznačen time da je za uporabu u postupku liječenja raka koji je rezistentan na jedno ili više sredstva protiv raka odabranih od cisplatina, karboplatina, i oksaliplatina.
21. Pripravak za uporabu u postupku liječenja raka prema zahtjevu 1 ili zahtjevu 20, naznačen time da je rak odabran od raka testisa, raka pluća malih stanica, i raka glave i raka vrata.
22. Pripravak za uporabu u postupku liječenja raka prema zahtjevu 1 ili zahtjevu 20, naznačen time da rak je rak jajnika.
23. Pripravak za uporabu u postupku liječenja raka prema bilo kojem zahtjevu 20 do 22, naznačen time da je izolirani monomerni kompleks platina kako je definirano u bilo kojem zahtjevu od 2 do 4.
24. Pripravak za uporabu u postupku liječenja raka prema zahtjevu 23, naznačen time da izolirani monomerni kompleks platine je (trans-1,2-cikloheksandiamin)(dihidrogen pirofosfato)platina(II).
25. Pripravak za uporabu u postupku liječenja raka prema zahtjevu 23, naznačen time da izolirani monomerni kompleks platine je (trans-1,2-cikloheksandiamin)-trans-dihidrokso(dihidrogen pirofosfato)platina(IV).
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US95412607P | 2007-08-06 | 2007-08-06 | |
| US97392607P | 2007-09-20 | 2007-09-20 | |
| PCT/US2008/072398 WO2009021082A2 (en) | 2007-08-06 | 2008-08-06 | Phosphaplatins and their use in the treatment of cancers resistant to cisplantin and carboplatin |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20140808T1 true HRP20140808T1 (hr) | 2014-10-24 |
Family
ID=40342030
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20140808AT HRP20140808T1 (hr) | 2007-08-06 | 2014-08-27 | Fosfaplatine i njihova uporaba za lijeäśenje raka rezistentnog na cisplantin i karboplatin |
Country Status (13)
| Country | Link |
|---|---|
| US (4) | US7700649B2 (hr) |
| EP (2) | EP2668949A1 (hr) |
| JP (2) | JP5385274B2 (hr) |
| CN (1) | CN101801369B (hr) |
| CY (1) | CY1115504T1 (hr) |
| DK (1) | DK2173337T3 (hr) |
| ES (1) | ES2495743T3 (hr) |
| HK (1) | HK1143551A1 (hr) |
| HR (1) | HRP20140808T1 (hr) |
| PL (1) | PL2173337T3 (hr) |
| PT (1) | PT2173337E (hr) |
| SI (1) | SI2173337T1 (hr) |
| WO (2) | WO2009021081A2 (hr) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2668949A1 (en) * | 2007-08-06 | 2013-12-04 | Ohio University | Phosphaplatins and their use in the treatment of cancers resistant to cisplatin and carboplatin |
| AP3480A (en) * | 2010-06-04 | 2015-12-31 | Univ Ohio | Phosphaplatins and their use for treatment of cancers |
| JP2014502634A (ja) | 2011-01-12 | 2014-02-03 | オハイオ ユニバーシティー | 抗血管新生、抗転移、及びアポトーシス促進の特性を有するホスファプラチン並びにそれらの使用 |
| US9284440B2 (en) | 2011-07-08 | 2016-03-15 | Dow Global Technologies Llc | Polyethylene blend composition suitable for blown film, method of producing the same, and films made therefrom |
| CA2851254A1 (en) | 2011-10-05 | 2013-04-11 | Shadi MOGHADDAS | Efficient processes for large scale preparation of phophaplatins antitumor agents |
| JP6027619B2 (ja) | 2011-10-05 | 2016-11-16 | ラシンドラ・エヌ・ボーズ | ホスファプラチン系抗腫瘍剤の大規模調製のための効率的プロセス |
| CN110269940A (zh) | 2011-10-20 | 2019-09-24 | 奈瑞姆生物技术公司 | 用于治疗癌症的治疗组合 |
| IN2014KN02722A (hr) | 2012-05-24 | 2015-05-08 | Phosplatin Therapeutics Llc | |
| US9333211B2 (en) * | 2013-02-22 | 2016-05-10 | University Of Houston System | Phosphaplatin mediated modulation of pigment epithelial derived factor and uses thereof |
| EP3107534A4 (en) * | 2014-02-19 | 2017-09-06 | The University Of Houston System | Compositions and methods for the treatment of neurodegenerative diseases |
| MX370673B (es) | 2014-06-11 | 2019-12-19 | Univ Texas | Conjugados y composiciones de texafirina-pt (iv) para su uso para superar la resistencia del platino. |
| EP3397642A1 (en) | 2015-12-30 | 2018-11-07 | Atilim Universitesi | Dna targeted mono and heterodinuclear complexes |
| EP3565561A4 (en) | 2017-01-06 | 2020-08-26 | Phosplatin Therapeutics LLC | PHOSPHAPLATIN COMPOUNDS AS THERAPEUTICS FOR THE TREATMENT OF BONE / BLOOD CANCER |
| AU2018327339B2 (en) * | 2017-09-08 | 2023-10-12 | Promontory Therapeutics Inc. | Phosphaplatin compounds as immuno-modulatory agents and therapeutic uses thereof |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4234500A (en) * | 1979-03-07 | 1980-11-18 | Engelhard Minerals & Chemicals Corporation | Ethylenediamine platinum(II) and 1,2-diamino-cyclohexane platinum(II) pyrophosphate complexes |
| US4291027A (en) | 1979-03-07 | 1981-09-22 | Engelhard Minerals & Chemicals Corp. | Method for treating tumors with ethylenediamine platinum (II) and 1,2-diaminocyclohexane-platinum (II) pyrophosphate complexes |
| CA2017739A1 (en) * | 1989-07-18 | 1991-01-18 | Leslie S. Hollis | Cis-diamineplatinum complexes with methanediphosphonate and substituted methanediphosphonate ligands as antitumor agents |
| EP1644388A2 (en) | 2003-06-27 | 2006-04-12 | ODANI, Akira | Bisphosphonate complexes |
| US20110034714A1 (en) * | 2007-07-06 | 2011-02-10 | Hisao Ekimoto | Metal complex compound, cancer therapeutic agent composition containing the metal complex compound as an active ingredient, and intermediate for the metal complex compound |
| EP2668949A1 (en) * | 2007-08-06 | 2013-12-04 | Ohio University | Phosphaplatins and their use in the treatment of cancers resistant to cisplatin and carboplatin |
-
2008
- 2008-08-06 EP EP13182512.7A patent/EP2668949A1/en not_active Withdrawn
- 2008-08-06 WO PCT/US2008/072397 patent/WO2009021081A2/en not_active Application Discontinuation
- 2008-08-06 WO PCT/US2008/072398 patent/WO2009021082A2/en active Application Filing
- 2008-08-06 EP EP08797320.2A patent/EP2173337B1/en active Active
- 2008-08-06 DK DK08797320.2T patent/DK2173337T3/da active
- 2008-08-06 ES ES08797320.2T patent/ES2495743T3/es active Active
- 2008-08-06 PT PT87973202T patent/PT2173337E/pt unknown
- 2008-08-06 CN CN2008801015774A patent/CN101801369B/zh active Active
- 2008-08-06 SI SI200831280T patent/SI2173337T1/sl unknown
- 2008-08-06 US US12/187,376 patent/US7700649B2/en active Active
- 2008-08-06 JP JP2010520294A patent/JP5385274B2/ja active Active
- 2008-08-06 PL PL08797320T patent/PL2173337T3/pl unknown
-
2010
- 2010-03-11 US US12/722,189 patent/US8034964B2/en active Active
- 2010-10-29 HK HK10110187.0A patent/HK1143551A1/xx unknown
-
2011
- 2011-08-30 US US13/221,458 patent/US8445710B2/en active Active
-
2013
- 2013-03-15 US US13/842,885 patent/US8653132B2/en active Active
- 2013-06-07 JP JP2013120309A patent/JP5647300B2/ja active Active
-
2014
- 2014-08-27 HR HRP20140808AT patent/HRP20140808T1/hr unknown
- 2014-08-27 CY CY20141100686T patent/CY1115504T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CY1115504T1 (el) | 2017-01-04 |
| PT2173337E (pt) | 2014-09-03 |
| US20090042838A1 (en) | 2009-02-12 |
| ES2495743T3 (es) | 2014-09-17 |
| US8445710B2 (en) | 2013-05-21 |
| EP2668949A1 (en) | 2013-12-04 |
| PL2173337T3 (pl) | 2014-11-28 |
| WO2009021081A3 (en) | 2009-05-07 |
| WO2009021081A2 (en) | 2009-02-12 |
| US8653132B2 (en) | 2014-02-18 |
| EP2173337A2 (en) | 2010-04-14 |
| EP2173337B1 (en) | 2014-07-30 |
| EP2173337A4 (en) | 2010-10-27 |
| JP2010535803A (ja) | 2010-11-25 |
| DK2173337T3 (da) | 2014-09-15 |
| HK1143551A1 (en) | 2011-01-07 |
| JP5647300B2 (ja) | 2014-12-24 |
| CN101801369A (zh) | 2010-08-11 |
| WO2009021082A2 (en) | 2009-02-12 |
| US20100233293A1 (en) | 2010-09-16 |
| JP5385274B2 (ja) | 2014-01-08 |
| US8034964B2 (en) | 2011-10-11 |
| CN101801369B (zh) | 2012-09-19 |
| US7700649B2 (en) | 2010-04-20 |
| US20130237503A1 (en) | 2013-09-12 |
| WO2009021082A3 (en) | 2009-04-23 |
| SI2173337T1 (sl) | 2014-10-30 |
| JP2013227218A (ja) | 2013-11-07 |
| US20110313182A1 (en) | 2011-12-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20140808T1 (hr) | Fosfaplatine i njihova uporaba za lijeäśenje raka rezistentnog na cisplantin i karboplatin | |
| CN100453703C (zh) | 一种控制二氧化碳腐蚀的缓蚀剂及其制备方法 | |
| JP2008538743A5 (hr) | ||
| JP2013227218A5 (hr) | ||
| EP2336139A3 (en) | Salts of isophosphoramide mustard and analogs thereof as anti-tumor agents | |
| JP2011520036A5 (hr) | ||
| HRP20170416T1 (hr) | Sintetski postupci i postupci pročišćavanja spojeva fosfaplatine i njihova uporaba | |
| HRP20110746T1 (hr) | Preparat stansoporfina sa visokim stupnjem čistoće | |
| CN106634377B (zh) | 一种适用于普通铝粉的水性闪光漆及其制备方法 | |
| CA2385927A1 (en) | Carbon monoxide source for the preparation of transition metal carbonyl complexes | |
| KR101598005B1 (ko) | 팔라듐 (하이드로겐)카보네이트와 아민 리간드의 착물의 제조 방법 | |
| WO2006001378A1 (ja) | Ｌ－オルニチン・クエン酸塩結晶 | |
| CN106634216B (zh) | 一种储存稳定的高耐候性水性陶瓷渗花墨水及其制法 | |
| CN106719681A (zh) | 一种油田杀菌缓蚀剂及其制备方法 | |
| CN105177071B (zh) | 一种生物法制备(s)-2-氨基-1-丁醇的方法 | |
| Bailar Jr et al. | The Role of Catalysis in the Preparation and Reactions of Some Cobaltic and Chromic Ammines | |
| MX2016006412A (es) | Composicion acuosa de recubrimiento por inmersion que comprende bismuto disuelto, para sustratos conductores de electricidad. | |
| Efremova et al. | Novel supramolecular compounds based on Cucurbit [6] uril, 1, 8-diaminooctane and octahedral thiohydroxo anions with cluster core [Re6S8] | |
| CN103183677A (zh) | 硫代硫酸铵作为还原剂在制备5-氨基-1,10-邻菲罗啉中的应用 | |
| CN103664707A (zh) | 酸式硫酸-β-氨基酯及其合成方法和应用 | |
| Lipunova et al. | Metallocomplexes of fluoroquinolonecarboxylic acids | |
| CN102701998A (zh) | 一种季铵盐起泡剂的制备方法 | |
| WO2010003969A3 (en) | New azo dyes | |
| Wang et al. | Methanol [4-nitro-2-(pyridin-2-ylmethyliminomethyl) phenolato](thiocyanato) copper (II) | |
| JP3612558B2 (ja) | シスプラチン耐性細胞に効く抗癌性白金錯体 |